Barclays analyst Luke Sergott maintained a Hold rating on Catalent (CTLT – Research Report) yesterday and set a price target of $47.00. The company’s shares closed yesterday at $59.82.
According to TipRanks, Sergott is an analyst with an average return of -3.8% and a 39.68% success rate. Sergott covers the Healthcare sector, focusing on stocks such as Danaher, Catalent, and Twist Bioscience.
The word on The Street in general, suggests a Hold analyst consensus rating for Catalent with a $51.11 average price target, implying a -14.56% downside from current levels. In a report released yesterday, Stephens also downgraded the stock to a Hold with a $63.50 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $74.49 and a one-year low of $31.45. Currently, Catalent has an average volume of 1.93M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Catalent (CTLT) Company Description:
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies; Biologics and Specialty Drug Delivery; Oral Drug Delivery; and Clinical Supply Services. The Softgel Technologies segment formulate, develop, and manufacture services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufacture services for blow-fill-seal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies, and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules, and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered in Somerset, NJ.
Read More on CTLT:
- M & A News: Novo Nordisk Announces $16.5B Catalent (NYSE:CTLT) Deal
- Catalent price target raised to $58 from $55 at RBC Capital
- Catalent Shareholders Approve Key Proposals at Annual Meeting
- Catalent’s 2023 Shareholder Meeting Approves Incentive Plan Amendment
- Early notable gainers among liquid option names on January 26th
